tbuckley/cabot-search huggingface dataset:
Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis
Authors: William J. Magnuson, Nataniel H. Lester-Coll, Abraham J. Wu, T. Jonathan Yang, Natalie A. Lockney, Naamit K. Gerber, Kathryn Beal, Arya Amini, Tejas Patil, Brian D. Kavanagh, D. Ross Camidge, Steven E. Braunstein, Lauren C. Boreta, Suresh K. Balasubramanian, Manmeet S. Ahluwalia, Niteshkumar G. Rana, Albert Attia, Scott N. Gettinger, Joseph N. Contessa, James B. Yu, Veronica L. Chiang
Journal: Journal of Clinical Oncology (2017)

Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for brain metastases in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). This multi-institutional analysis sought to determine the optimal management of patients with EGFR-mutant NSCLC who develop brain metastases and have not received EGFR-TKI. Materials and Methods A total of 351 patients from six institutions with EGFR-mutant NSCLC developed brain metastases and met inclusion criteria for the study. Exclusion criteria included prior EGFR-TKI use, EGFR-TKI resistance mutation, failure to receive EGFR-TKI after WBRT/SRS, or insufficient follow-up. Patients were treated with SRS followed by EGFR-TKI, WBRT followed by EGFR-TKI, or EGFR-TKI followed by SRS or WBRT at intracranial progression. Overall survival (OS) and intracranial progression-free survival were measured from the date of brain metastases. Results The median OS for the SRS (n = 100), WBRT (n = 120), and EGFR-TKI (n = 131) cohorts was 46, 30, and 25 months, respectively ( P < .001). On multivariable analysis, SRS versus EGFR-TKI, WBRT versus EGFR-TKI, age, performance status, EGFR exon 19 mutation, and absence of extracranial metastases were associated with improved OS. Although the SRS and EGFR-TKI cohorts shared similar prognostic features, the WBRT cohort was more likely to have a less favorable prognosis ( P = .001). Conclusion This multi-institutional analysis demonstrated that the use of upfront EGFR-TKI, and deferral of radiotherapy, is associated with inferior OS in patients with EGFR-mutant NSCLC who develop brain metastases. SRS followed by EGFR-TKI resulted in the longest OS and allowed patients to avoid the potential neurocognitive sequelae of WBRT. A prospective, multi-institutional randomized trial of SRS followed by EGFR-TKI versus EGFR-TKI followed by SRS at intracranial progression is urgently needed.
Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia
Authors: Dina Stroopinsky, Hasan Rajabi, Maxwell Douglas Coll, Athalia Rachel Pyzer, Jacalyn Rosenblatt, Salvia Jain, Katarina Luptakova, Malgorzata McMasters, James D. Levine, Robin Joyce, Jon E. Arnason, Rebecca Karp Leaf, Myrna Rita Nahas, Kristen Anna Palmer, Michal Bar-Natan, Ashujit Tagde, Abigail Washington, Poorvi Somaiya, Donald Kufe, David Avigan
Journal: Blood (2015)
ATR-Chk1 Axis Is Activated, but the Function of Chk1 Is Disrupted in BCR/ABL Leukemia Cells Responding to DNA Damage.
Authors: Margaret Nieborowska, Tomasz Stoklosa, Mandrita Datta, Agnieszka Czechowska, Lori Rink, Janusz Blasiak, Tomasz Skorski
Journal: Blood (2005)
Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.
Authors: Daniel A. Pollyea, Andrew S. Artz, Wendy Stock, Lucy Godley, Olatoyosi M. Odenike, Elizabeth Rich, Sonali M. Smith, Richard Larson, Koen Van Besien
Journal: Blood (2005)
Specific N- and O-Linked Carbohydrate Structures Mediate Von Willebrand Factor Interaction with Galectins -1 and -3
Authors: Orla Rawley, Jamie O'Sullivan, Gudmundur Bergsson, Alain Chan, Rachel Therese McGrath, Maartje van den Biggelaar, Jan Voorberg, Vince Jenkins, James S O'Donnell
Journal: Blood (2011)
RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients
Authors: Jeffrey W Tyner, Marc Loriaux, Stephanie G Willis, Bill Chang, Vincent T Bicocca, Stephen Oh, Iris H.I.M. Hollink, Stefanie Segers, Monique L. den Boer, C. M Zwaan, Jason R. Gotlib, Michael W.N. Deininger, Brian J. Druker
Journal: Blood (2008)
Activated Chronic Lymphocytic Leukemia B-Cells Preferentially Shed CD52+ Microvesicles, but Not CD19+, and May Predict Therapeutic Outcome
Authors: Sutapa Sinha, Justin Boysen, Michael Nelson, Connie Lesnick, Tait D. Shanafelt, Neil E. Kay, Asish K Ghosh
Journal: Blood (2014)
A phase I QTc study of tivozanib in patients with advanced solid tumors.
Authors: Manpreet Kaur Chadha, Jeffrey R. Infante, Monette M. Cotreau, Lindsey Jacobson, Andrew Louis Strahs, William Slichenmyer, Dennis Vargo, Kathleen N. Moore
Journal: Journal of Clinical Oncology (2012)

445 Background: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors-1, -2, and -3 that is currently being tested in a Phase III study in patients with renal cell carcinoma and Phase I/II studies of other solid tumors. Preclinical and retrospective electrocardiogram (ECG) analyses suggest no effect of tivozanib on QTc, although this has not been prospectively assessed according to ICH E14 Cardiac Assessment of New Drugs Guidelines. This open-label, non-randomized, single-arm study prospectively investigated the effect of tivozanib on the QTcF interval and its morphology on the ECG and ECG-pharmacokinetic (PK) relationship in patients with advanced solid tumors. Methods: Patients with advanced solid tumors, an ECOG score ≤1 and life expectancy ≥3 months were eligible. Patients received 1.5 mg of tivozanib orally, once daily for 21 days. Serial blood samples and time-matched, triplicate, 12-lead ECGs were collected on: Day 1 20-30 minutes pre-dose (no blood sample collected), immediately pre-dose, and at 2.5, 4, 5, 6, 8, and 10 hours post dose; Day 2 pre-dose evaluation was taken approximately 24 hours post Day 1 dose; Day 8 (±1 day) pre-dose, and at 2.5, 5, and 8 hours post dose; Day 21 pre-dose and at 2.5, 4, 5, 6, 8, and 10 hours post dose; and Day 22 at approximately 24 hours post Day 21 dose. Additional safety parameters were evaluated by assessing clinical laboratory tests, physical examinations, vital signs, and recording of adverse events. Results: Fifty patients with advanced solid tumors (males, 17; median age, 63 years; 94% white) who received ≥ 1 dose of tivozanib were evaluable. Preliminary data showed that there were no clinically significant changes in QTcF from baseline. Further analysis will be completed, and final safety and ECG-PK modeling will be presented. Conclusions: Preliminary data suggest that tivozanib 1.5 mg/d over a 21-day period does not cause clinically significant QT/QTc prolongation over baseline, suggesting that its safety and PK profile is similar to that observed in previous studies, including ECG evaluation in a monkey telemetry study.
Post-Ebola reforms: ample analysis, inadequate action
Authors: Suerie Moon, Jennifer Leigh, Liana Woskie, Francesco Checchi, Victor Dzau, Mosoka Fallah, Gabrielle Fitzgerald, Laurie Garrett, Lawrence Gostin, David L Heymann, Rebecca Katz, Ilona Kickbusch, J Stephen Morrison, Peter Piot, Peter Sands, Devi Sridhar, Ashish K Jha
Journal: BMJ (2017)

Reports on the response to Ebola broadly agree on what needs to be done to deal with disease outbreaks. But <b>Suerie Moon and colleagues</b> find that the world is not yet prepared for future outbreaks
Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood
Authors: J. S. Ford, J. Schwartz, L. N. McCallen, M. J. Matasar, J. N. Butos, E. R. Riedel, D. M. Weinstock, K. C. Oeffinger, D. J. Straus
Journal: Journal of Clinical Oncology (2008)

9592 Background: The prognosis of patients with Hodgkin lymphoma (HL) has markedly improved over the past three decades, but little is known about the psychosocial functioning of long-term survivors. Methods: We administered a self-report survey to patients treated as adults on first-line therapy protocols for HL at our center from 1975–2000. Quality of life, fatigue, fears of recurrence, and mood were assessed using the SF-12, FACIT-fatigue, Fears of Recurrence Questionnaire (FRQ), and Hospital Anxiety and Depression Scale (HADS). Results: Of 707 pts for whom follow-up was available, 514 were alive; median survival was 29y. Survey data were available for 186 pts, with a median time from last treatment of 21y. Median age at interview was 48y (range, 25–88) and median age at treatment initiation was 30y (range, 14–66). 52% were women, 96% were white non-Hispanic, 80% were married or living with a partner, and almost 61% had at least a college education. Past treatment for HL was reported to interfere with careers (18%), working full time (11%), and completing household chores (9%). A surprisingly high number of HL survivors (17%) reported having depression (90% of who were on psychotropic medications) or anxiety (12%). On the HADS, 6% met clinical cutoff scores for depression and another 6.5% scored in the borderline range. 16% exceeded the clinical cutoff scores for anxiety and another 11% were in the borderline range. About one-third of participants rated their quality of life (physical and mental functioning) as fairly low. Over 80% of survivors reported high fears of recurrence or second cancers. Younger age at treatment was associated with greater prevalence (p=0.02) of psychiatric dysfunction. Conclusions: Psychosocial morbidity occurs in a significant proportion of long-term survivors of HL treated as adults. Additional analyses will identify high-risk sub-groups of survivors in need of psychological and psychiatric interventions. No significant financial relationships to disclose.
Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.
Authors: Heinz Ludwig, Johannes Drach, Elena Tóthová, Heinz Gisslinger, Werner Linkesch, Boris Jaksic, Michael Fridik, Josef Thaler, Alois Lang, Roman Hajek, Niklas Zojer, Richard Greil, Ingrid Kuhn, Axel Hinke, Boris Labar
Journal: Blood (2005)
A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.
Authors: Utz O. Krug, Achim Heinecke, Anja Koschmieder, Matthias Stelljes, Maria Cristina Sauerland, Wolfgang E Berdel, Bernhard J Woermann, Wolfgang Hiddemann, Thomas Buchner, Carsten Müller-Tidow
Journal: Blood (2009)
Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).
Authors: Athanasios G. Galanopoulos, Stephanos Papadhimitriou, Ioannis Tsourveloudis, Evridiki Michalis, Theodoros Marinakis, Anastasia Tsakiridou, Ioanna Savvidou, Vasilios Xanthopoulos, George Theodoropoulos, George Gortzolidis, Athanasios Zomas, Maria Georgiakaki, Nikolaos I. Anagnostopoulos
Journal: Blood (2005)
Is It Time for Arraycgh to Be the First Line Test for Detection of Chromosome Abnormalities in Hematological Disorders-Example Multiple Myeloma
Authors: Ankita Patel, Patricia Hixson, Weimin Bi, Caroline Borgan, Marcus Coyle, Danielle Freppon, David Vo, Jacqueline T. O'Hare, Patricia Luke, Chung-Che Chang, Sau Cheung
Journal: Blood (2011)
No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors
Authors: Petra J. Woestenberg, Audrey J. King, Marianne A.B. van der Sande, Robine Donken, Suzan Leussink, Fiona R.M. van der Klis, Christian J.P.A. Hoebe, Johannes A. Bogaards, Birgit H.B. van Benthem, D. Adema, R. Buist-Arkema, A. Beerens, D. Luijt, S. Meijer, J. Schirm, A. Buiting, M. Peeters, J. Rossen, H. Verbakel, P. van Esch, J. Verweij, A. van der Eijk, R. Huisman, C. Kerkhof, H. Korff, M. Schutten, J. Velzing, F. Verduyn-Lunel, S. Lakbiach, P. van Rosmalen, R. Schuurman, D. Abma, K. Adams, S. Bruisten, I. Linde, P. Oostvogel, C. Touwen, W. Vermeulen, A. Brink, J. Nelissen, P. Wolffs, N. Duijvendijk, P. Schneeberger, M. Dinnissen-van Poppel, W. Melchers, Y. Poort, M. Hooghiemstra, H. Huisman, J. Weel, H. Bosch, T. de Haas, R. Kleinspenkelink, I. Polman, T. Smits, P. van Goor, M. Wolfhagen, C. de Mooij, E. van Koolwijk, M. Peters, C. Swanink, R. Tiemessen, T. van Zwet, J. Janssen, M. Pelsers, W. de Waal, G. Aalfs, J. Kiewiet, P. Sanders, H. van Buel-Bruins, C. van Bokhoven-Rombouts, P. Cornelissen, M. Kersten, C. van Ruitenbeek, I. Molenaar, E. Doorn, L. Masthoff, E. Pannekoek, V. Sigurdsson, H. Götz, M. Illidge-Onder de Linden, M. Mattijssen, J. Stam, E. Swaders, F. de Groot, F. Postma, E. Brouwers, A. Niekamp, M. Smit, A. Botraby, D. Bukasa, C. de Haan, P. Hut-van Vliet, T. Taconis, M. de Graas, I. Hondelink, C. Kampman, A. Gelissen-Hansen, I. de Koning, H. van Kruchten, M. van de Pas, H. Fennema, T. Heijman, A. Hogewoning, A. van Leeuwen, M. van Rooijen, F. Neienhuijsen, M. Pelgrim
Journal: Journal of Infection (2017)

ObjectivesData from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands.MethodsWe included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior.ResultsOf the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74–1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22–2.07) for women vaccinated at least once. Adjustment did not change these results.ConclusionsWe observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW.
Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,
Authors: Catherine S. Diefenbach, Rachel Sabado, Christopher L. Brooks, Jairo Baquero-Buitrago, Crystal Cruz, Isabelita Vengco, Francesca Montanari, Enrica Marchi, Luigi Scotto, Thomas P. Cirrito, Ivan Bergstein, Owen A. O'Connor
Journal: Blood (2011)
Synthesis of Medium‐Chain‐Length Polyhydroxyalkanoate Homopolymers, Random Copolymers, and Block Copolymers by an Engineered Strain of <i>Pseudomonas entomophila</i>
Authors: Ying Wang, Ahleum Chung, Guo‐Qiang Chen
Journal: Advanced Healthcare Materials (2017)

Medium-chain-length polyhydroxyalkanoates (mcl-PHAs), widely used in medical area, are commonly synthesized by Pseudomonas spp. This study tries to use β-oxidation pathways engineered P. entomophila to achieve single source of a series of mcl-monomers for microbial production of PHA homopolymers. The effort is proven successful for the first time to obtain a wide range of mcl-PHA homopolymers from engineered P. entomophila LAC23 grown on various fatty acids, respectively, ranging from poly(3-hydroxyheptanoate) to poly(3-hydroxytetradecanoate). Effects of a PHA monomer chain length on thermal and crystallization properties including the changes of Tm , Tg , and Td5% are investigated. Additionally, strain LAC23 is used to synthesize random copolymers of 3-hydroxyoctanoate (3HO) and 3-hydroxydodecanoate (3HDD) or 3-hydroxytetradecanoates, their compositions could be controlled by adjusting the ratios of two related fatty acids. Meanwhile, block copolymer P(3HO)-b-P(3HDD) is synthesized by the same strain. It is found for the first time that even- and odd number mcl-PHA homopolymers have different physical properties. When the gene of the PHA synthase in the engineered P. entomophila is replaced by phaC from Aeromonas hydrophila 4AK4, poly(3-hydroxybutyrate-co-30 mol%-3-hydroxyhexanoate) is synthesized. Therefore, P. entomophila can be used to synthesize the whole range of PHA (C7-C14) homopolymers, random- and block copolymers.
The need for a new Tobacco Control Plan: an issue of justice
Authors: Nicholas S Hopkinson, Jane Dacre, Lesley Regan, Helen Stokes-Lampard, Simon Wessely, Neena Modi, John Middleton, Andrew Furber, Parveen Kumar, Penny Woods, John Moxham, Shirley Cramer, Richard Thompson, Ian Gilmore, Carol Black, George Alberti, Margaret Turner-Warwick, Sheila Hollins, Cyril Chantler, Hilary Cass
Journal: BMJ (2017)

The prime minister’s commitment to “fighting against the burning injustice that if you’re born poor, you will die on average nine years earlier than others”1 is welcome and achievable. As her government has acknowledged,2 half of this difference in life expectancy is due to the higher rates of smoking among the least affluent, so major improvements can …
Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma
Authors: Vassilis L. Souliotis, Maria Gkotzamanidou, Petros P. Sfikakis, Evangelos Terpos, Christos Papadimitriou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Nikitas Nikitas, Efstathios Kastritis, Soterios A. Kyrtopoulos, Meletios A. Dimopoulos
Journal: Blood (2010)
microRNA Control of Hematopoietic Stem Cell Fitness and Myelopoiesis.
Authors: Chinavenmeni S. Velu, Sarah Porteous, Haiming Xu, Avinash M. Baktula, Philip Roehrs, Tristan Bourdeau, Ed Stavnezer, David Williams, Clemencia Colmenares, H. Leighton Grimes
Journal: Blood (2007)
Venous Thromboembolism (VTE) Characteristics among White- and Black-Americans: a Cross Sectional Study
Authors: John A. Heit, Michele Beckman, Althea Grant, Nigel S. Key, Marilyn J. Manco-Johnson, Stephan Moll, Paula Bockenstedt, Roshni Kulkarni, Thomas L. Ortel, Claire S. Philipp
Journal: Blood (2008)
Disrupted Toll-Like Receptor Signalling Of Intestinal Epithelium In Intestinal Graft-Versus-Host Disease
Authors: Can Liu, Meiqing Wu, Ke Zhao, Xiuli Wu, Yu Zhang, Zhiping Fan, Qian Fan, Changxin Yin, Zhongxin Zheng, Zhengshan Yi, Qifa Liu
Journal: Blood (2013)
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.
Authors: Michael D. Staehler, Lothar Bergmann, Viktor Grünwald, Torsten Huschke, Ulrich Keilholz, Carsten Henning Ohlmann, Michael Stöckle, Karin Weigang-Koehler, Kirsten Hauswald, Felix Schaller, Luise Strassl, Kerstin Junker
Journal: Journal of Clinical Oncology (2012)

467 Background: Clinical research in mRCC is leading to increased treatment options. Most patients (pts) are treated with sequenced systemic medications based on the clinical course of the disease. Characterization of pts most likely to benefit from a specific targeted agent has not yet been sufficiently addressed in this area. So far, no reliable biomarkers exist to predict therapy response or resistance in the individual patient. Further investigation is needed to understand drug effects in vivo. In the MARC-2-study, pts treated with everolimus will be characterized by serum and tissue biomarkers in order to identify a pattern possibly suggestive of treatment outcome. Methods: 80 pts are to be enrolled at about 15 study centers in Germany over 2 years. Major inclusion criteria are confirmed predominantly clear cell mRCC, failure of exactly 1 prior VEGFR-TKI therapy, no pretreatment with mTOR inhibitors or bevacizumab. Tumor response is assessed according to RECIST 1.1. Safety assessments include monitoring of adverse events and laboratory parameters. Primary objective is the rate of pts free of disease progression after 6 months of treatment. Secondary objectives are relation of biomarkers to the clinical benefit, progression free survival, overall survival, objective response rate and safety profile. For explorative assessments, blood samples are taken pre-treatment and at prespecified time points during the treatment. Central histopathological classification of tumor samples will be performed. Biomarker projects include: Serum protein profiling by using SELDI-TOF-MS; quantification of Treg cells in blood samples; identification of serum metabolic biomarkers; polymorphisms in genes related to the VEGFR signaling pathway; expression analysis of the mTOR-pathway in tumor samples. Pharmacokinetic consists of everolimus trough levels. Tumor assessments by functional MRI will be performed within a substudy at selected sites. Results: The 1 st patient was enrolled in 03/2011. Until 08/2011, 10 sites have been initiated and 9 pts were recruited. Conclusions: The new project MARC-2 was introduced and started successfully in 2011.
Review: Pregabalin reduces fibromyalgia pain but increases adverse events
Authors: Michael Yelland
Journal: Annals of Internal Medicine (2017)

ACP Journal Club17 January 2017Review: Pregabalin reduces fibromyalgia pain but increases adverse eventsMichael Yelland, MBBS, PhDMichael Yelland, MBBS, PhDGriffith University, Gold Coast, Queensland, Australia (M.Y.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-166-2-002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationDerry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9:CD011790. https://pubmed.ncbi.nlm.nih.gov/27684492Clinical Impact RatingsGIM/FP/GP: Neurology: Rheumatology: References1 Nasser K, Kivitz AJ, Maricic MJ, Silver DS, Silverman SL. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken). 2014;66:293-300. [PMID: 23983064] Google Scholar2 Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2015;10:CD008244. [PMID: 26482422] Google Scholar3 Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115. [PMID: 24385423] Google Scholar4 Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions—individual patient data responder analysis. Eur J Pain. 2014;18:67-75. [PMID: 23733529] Google Scholar5 Gilron I, Chaparro LE, Tu D, et al. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 2016;157:1532-40. [PMID: 26982602] Google Scholar Author, Article, and Disclosure InformationAffiliations: Griffith University, Gold Coast, Queensland, Australia (M.Y.)This article was published at Annals.org on 3 January 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCitronellol, a monoterpene alcohol with promising pharmacological activities - A systematic reviewFibromyalgia and unexplained widespread pain: The idiopathic cerebrospinal pressure dysregulation hypothesis 17 January 2017Volume 166, Issue 2Page: JC2KeywordsAdverse eventsFibromyalgiaRelative riskRheumatic painRheumatologyRisk ratioSafetySerious adverse eventsSleepWeight gain ePublished: 17 January 2017 Issue Published: 17 January 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Silk-based anisotropical 3D biotextiles for bone regeneration
Authors: Viviana P. Ribeiro, Joana Silva-Correia, Ana I. Nascimento, Alain da Silva Morais, Alexandra P. Marques, Ana S. Ribeiro, Carla J. Silva, Graça Bonifácio, Rui A. Sousa, Joaquim M. Oliveira, Ana L. Oliveira, Rui L. Reis
Journal: Biomaterials (2017)